publication . Article . 2017

Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection

Anne W. Rimoin; Kai Lu; Matthew S. Bramble; Imke Steffen; Reena H. Doshi; Nicole A. Hoff; Patrick Mukadi; Bradly P. Nicholson; Vivian H. Alfonso; Gerrard Olinger; ...
Open Access
  • Published: 14 Dec 2017 Journal: The Journal of Infectious Diseases, volume 217, issue 2, pages 223-231 (issn: 0022-1899, eissn: 1537-6613, Copyright policy)
  • Publisher: Oxford University Press (OUP)
Abstract
Duration of immunity against Ebola virus among survivors remains unclear. We assessed serological immune profiles and retention of Ebola virus neutralizing antibodies in 14 survivors of the 1976 Yambuku outbreak 40 years postinfection, providing the longest documentation of such measures reported.
Persistent Identifiers
Subjects
Medical Subject Headings: virusesvirus diseaseshumanitiesbiochemical phenomena, metabolism, and nutrition
free text keywords: Infectious Diseases, Immunology and Allergy, Humans, Hemorrhagic Fever, Ebola, Antibodies, Viral, Antigens, Enzyme-Linked Immunosorbent Assay, Neutralization Tests, Disease Outbreaks, Time Factors, Adolescent, Adult, Aged, 80 and over, Middle Aged, Survivors, Democratic Republic of the Congo, Female, Male, Ebolavirus, Young Adult, Neutralizing, Viral Plaque Assay, Surveys and Questionnaires, Ebola virus, filovirus, serological response, virus neutralization, and over, Microbiology, Biological Sciences, Medical and Health Sciences, Major Articles and Brief Reports, Viruses, Ebola virus, Democratic Republic of the Congo, virus neutralization, serological response, filovirus, Outbreak, Serology, VP40, Virology, Ebola virus, medicine.disease_cause, medicine, Neutralization, Antibody, biology.protein, biology, Plaque reduction neutralization test, business.industry, business, Virus
Funded by
NIH| Serological prevalence of viral hemorrhagic fevers in Equatorial Africa
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R21AI107420-02
  • Funding stream: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
,
NIH| University of California Global Health Institute Program for Fellows and Scholars
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5D43TW009343-07
  • Funding stream: FOGARTY INTERNATIONAL CENTER
Communities
COVID-19
32 references, page 1 of 3

1.Beeching NJ Fenech M Houlihan CF Ebola virus disease. BMJ 2014; 349:g7348.25497512 [OpenAIRE] [PubMed]

2.Anon. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56:271–93.307456 [OpenAIRE] [PubMed]

3.Centers for Disease Control and Prevention. Cases of Ebola virus disease in Africa, 1976–2015. https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html. Accessed 14 March 2016.

4.Maganga GD Kapetshi J Berthet N Ebola virus disease in the Democratic Republic of Congo. N Engl J Med 2014; 371:2083–91.25317743 [PubMed]

5.WHO Ebola Response Team, Aylward B Barboza P Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371:1481–95.25244186 [OpenAIRE] [PubMed]

6.Muyembe-Tamfum JJ Mulangu S Masumu J Kayembe JM Kemp A Paweska JT Ebola virus outbreaks in Africa: past and present. Onderstepoort J Vet Res 2012; 79:451.23327370 [PubMed]

7.Breman JG Heymann DL Lloyd G Discovery and description of Ebola Zaire virus in 1976 and relevance to the West African epidemic during 2013–2016. J Infect Dis 2016; 214 Suppl 3:S93–101.27357339 [OpenAIRE] [PubMed]

8.Rosello A Mossoko M Flasche S Ebola virus disease in the Democratic Republic of the Congo, 1976–2014. Elife 2015; 4.

9.Natesan M Jensen SM Keasey SL Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses. Clin Vaccine Immunol 2016; 23:717–24.27335383 [OpenAIRE] [PubMed]

10.Corti D Misasi J Mulangu S Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 2016; 351:1339–42.26917593 [PubMed]

11.Bond N Schieffelin JS Moses LM Bennett AJ Bausch DG A historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infection. Am J Trop Med Hyg 2013; 88:241–4.23390223 [OpenAIRE] [PubMed]

12.Johnson KM Webb PA Heymann DL Evaluation of the plasmapheresis program in Zaire. Ebola virus hemorrhagic fever. In: Pattyn SR (ed). Ebola virus hemorrhagic fever. Amsterdam: Elsevier, 1978.

13.World Health Organization. Case definition recommendations for Ebola or Marburg Virus Diseases. Technical Guidelines for Integrated Disease Surveillance and Response (IDS) in the Africa Region. Geneva: World Health Organization, 2014.

14.Yang ZY Duckers HJ Sullivan NJ Sanchez A Nabel EG Nabel GJ Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000; 6:886–9.10932225 [OpenAIRE] [PubMed]

15.Burbelo PD Goldman R Mattson TL A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol 2005; 5:22.16109166 [OpenAIRE] [PubMed]

32 references, page 1 of 3
Any information missing or wrong?Report an Issue